Genomics and Molecular Diagnostics Technology and Treatment Center


Understanding the molecular landscape of cancer has facilitated the development of diagnostic, prognostic, and predictive biomarkers for clinical oncology. Recent developments in the field of targeted therapies for cancer have added to the huge demand for accurate, faster, and large-scale DNA sequencing technologies.

Developments in next-generation DNA sequencing technologies have reduced turn-around time and sequencing costs remarkably. This has unlocked opportunities to characterize the genomic and transcriptomic landscapes of cancer for translational research.


Molecular diagnostics could be a potential tool for screening patients with newly diagnosed cancers and their family members for risk predispositions to reduce morbidity and mortality.

Cancer Genomics and Precision Diagnostics at HCG

Triesta Sciences, a unit of HealthCare Global (HCG) Enterprises Limited, is a one-stop solution for cancer diagnostics, genomics (next-generation sequencing-based diagnostics), biomarker and translational research, laboratory services, and clinical research services.

The Department of Molecular and Clinical Genomics at Triesta is a state-of-the-art genomics center offering comprehensive diagnostics based on next-generation sequencing to patients of all geographies to improve therapy selection, predict response and prognosis, screen for hereditary cancers, and predict predisposition and risk.

We study the genomic profiling data of tumor samples and provide robust analysis and biological interpretation of the large data sets using analytics and interpretation platforms. Along with this and the constant addition of new technologies like liquid biopsy, genomics, and translational research, Triesta is geared up to be one of the most advanced labs globally.


Adopt and contribute to an emerging medical discipline called “Genomic Medicine”.

Implement genetic testing as the standard of care for treating cancer at an affordable cost for all patients through the use of genomic data from patients for better diagnosis, effective therapeutic decisions, and overall improved health outcomes.

Help patients achieve longer and better lives and improve outcomes.

An in-depth understanding of the genetic profile of cancer cells will enable us to adopt innovative diagnostic and treatment protocols, contribute to an emerging medical discipline called “Genomic Medicine”, and develop novel therapeutic drugs and technologies to offer individualized treatment for each cancer case, as every patient is different. The robust database generated from this project will help us find new genetic alterations in cancer cells and correlate these alterations to the therapeutic response. This approach will eventually help the clinicians stratify the patients into responders and non-responders effectively and offer them the “right treatment at the first time.”

With a high disease burden, a large patient base at the hospital, seamless availability of a well-annotated tissue biorepository, fully maintained clinical data, and the strong clinical excellence of the oncologists and scientists at “The Center of Cancer Genomics”, we are best placed to study the genomic profiling data of tumor samples and provide robust analysis and biological interpretation of the large data using an analytics and interpretation platform. By doing this, Triesta Sciences takes leadership in cancer genetics and develops a “Genomic Bank” with complete clinical and genomic data.

Genomic Profiling at HCG

HCG has profiled over 2000+ patients with a variety of malignancies using targeted deep sequencing for hotspot mutations in 56 cancer-related genes, a mid-size panel of 152 genes, and a bigger gene panel of 500 genes.

Comprehensive Genomic Profiling (CGP) using the TSO 500 gene panel includes SNVs, CNVs, translocations, fusions, microsatellite instability, and Tumor Mutation Burden (TMB).

HCG has also profiled patients associated with the risk of hereditary cancers using both amplicon and enrichment-based technologies via the Miseq and Nextseq platforms. Somatic mutations identified in the tumor were assessed for “actionability,” i.e., impact on prognosis and response to therapy.

The genetic profiles of these patients were linked to clinicopathological parameters. In 45% of patients, actionable mutations were identified and reported to the treating clinicians to assist in treating the patients. About 45% of patients had mutations that were of prognostic and predictive relevance. The results of this pilot study have resulted in more than 10 academic presentations and publications all over the world. Our data from this pilot study suggest that targeted deep sequencing using a multi-gene panel approach can yield useful therapeutic and prognostic insights in a wide range of tumor types.

Liquid Biopsy Research

Liquid biopsy is a new technique that has emerged and has great applicability in the field of personalized cancer treatment. Presently, there is a lack of clinically approved, specific circulating biomarkers in blood and plasma. Few markers like CA-125, CA-15-3, CEA, PSA, etc. do exist, but they are limited to some cancers only, and they only work well in cases of metastatic cancers when the tumor burden is high. These same markers are also expressed in normal individuals in lower amounts and, hence, are not very cancer-specific. We also know that cancer is a genetic disease, and the genetics of the tumor can give an in-depth knowledge of tumor biology.

Genetic sequencing and testing are not the latest technologies. However, limitations like the heterogeneity of the solid tumors, the unavailability of the sample post-surgery, and the inability to biopsy an inaccessible tumor exist. Also, since tumors continuously evolve and change in response to therapy, periodic monitoring is a challenge. Hence, liquid biopsies have emerged as an important way to overcome these challenges, where circulating tumor cells (CTC) and cell-free DNA (cfDNA) are isolated and examined, and the results from these analyses help doctors make informed clinical decisions.

Frequently Asked Questions

For any cancer to be treated successfully, it has to be diagnosed accurately. By employing molecular diagnostics in cancer care, we can:

Deliver actionable and accurate diagnostic results

Detect health anomalies that are missed during other tests

Help patients make informed health decisions quickly by delivering the test results in a shorter time frame.

These aspects make molecular diagnostics a reliable tool in cancer care.

There are various molecular diagnostic protocols available that help determine whether a person is at risk for a particular cancer type. These tests are particularly helpful for individuals with a family history of a specific cancer type.

Over the years, molecular biologists have come up with numerous protocols to look for specific mutations, the presence of specific biomarkers or proteins, etc., that help determine an individual’s chance of developing cancer.

Yes, molecular diagnostic protocols are extremely helpful in the early detection of a few cancer types. Let us take breast cancer, for instance. Molecular biologists look for mutations in the BRCA1 and BRCA2 genes, which are responsible for the increased risk of the disease.

Molecular diagnostic protocols can catch various cancer types years before they start showing symptoms. This way, molecular diagnostics can also support timely medical intervention.

HCG believes in delivering value-based medicine; in other words, it aims to provide the right treatment the first time to every patient. Value-based medicine is supported by accurate diagnosis, which in turn can be made possible by molecular diagnostics.

Our oncologists and molecular biologists are working hand in hand to devise a myriad of molecular diagnostic protocols that will help patients have multiple treatment options. By making diagnosis more extensive, HCG aims to help patients and family members make informed health decisions.